EVALUATION OF SERUM IRISIN WITH LIPID PROFILE IN TYPE-2 DIABETIC PATIENTS IN SULAIMANI

Fenk Bakir Maarouf a, Mohammed O. Mohammed b, Nazaneen Akbar Omer aand Beston Faiek Nore a, c




a Department of Biochemistry, College of Medicine, University of Sulaimani. 
b Department of Medicine, College of Medicine, University of Sulaimani. 
c Department of Health, Kurdistan Institution for Strategic Studies and Scientific Research, Sulaimani.

Submitted: 26/5/2018; Accepted: 12/8/2018; Published 15/10/2018
ABSTRACT


Background 

Obesity has become one of the most growing global risk factor for many diseases and metabolic disorders, including Type -2 Diabetes Mellitus (T2DM). Irisin is a recently discovered myokine hormone and has a primary structure of 112 amino acids. It is expressed and secreted by muscles in response to physical activities that control obesity and delay insulin resistance. Several studies show decrease in Irisin levels in a number of metabolic disorders, but the Irisin status is unknown in diabetic patients in our region.


Objectives 

To evaluate the level of serum Irisin with serum lipid profile in T2DM patients.



Patients and Methods

This study was carried out on 256 individuals, 156 T2DM patients (study group) and 100 non-diabetic individuals (control group) in Sulaimani diabetic centre. The serum level of irisin, glucose, urea, creatinine, lipid profile, and glycated hemoglobin were determined using biochemical and immunological methods. Statistical analysis was performed using STATA 14 software.


Results

The mean serum Irisin level was significantly higher (P<0.01) in the control group compared to T2DM (3.34±1.48 vs. 1.82±1.44) respectively. The body mass index (BMI) was significantly higher in T2DM patients (31.06 ±5.3) compared to the control (28.55±3.9). The levels of total cholesterol, triglyceride (TG) and low-density lipoprotein (LDL) were significantly higher in T2DM, while high-density lipoprotein (HDL) was lower in T2DM compared to the control. The Atherogenic Index of plasma (AIP) was significantly higher inT2DM (1.9±0.44) compared to the control (1.2±0.59). There was a significant inverse association (p<0.001) between AIP and serum Irisin in both groups. 


Conclusions

Serum Irisin was significantly lower in T2DM compared to non-diabetic control. There was a significant inverse correlation between serum Irisin and AIP in both groups. However, there was no significant correlation between serum Irisin with age, gender and BMI in both groups. 



KEYWORDS

Irisin, T2DM, BMI, Obesity, Atherogenic Index, Lipid profile.